Nationwide Fund Advisors Nektar Therapeutics Transaction History

Nationwide Fund Advisors

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2017 Feb 01, 2018	SELL	$23.02 - $60.5 $4.14 Million - $10.9 Million	-179,877 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$17.79 - $24.0 $1.29 Million - $1.74 Million	72,322 Added 67.24%	179,877 $4.32 Million
Q2 2017 Aug 10, 2017	BUY	N/A	107,555	107,555 $2.1 Million

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $246M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Nationwide Fund Advisors, based on Form 13F filings with the SEC.

Stay updated on Nationwide Fund Advisors with notifications on news.